Overview

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status:
NOT_YET_RECRUITING

Trial end date:
2026-09-30

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler compared with the placebo in the treatment of Chinese patients with COPD.

Phase:

PHASE2

Details

Lead Sponsor:

Haisco Pharmaceutical Group Co., Ltd.